<DOC>
	<DOCNO>NCT00355186</DOCNO>
	<brief_summary>Title : SWiss multicenter Intracoronary Stem cell Study Acute Myocardial Infarction ( SWISS-AMI ) . Study population : Patients acute myocardial infarction , treat primary PCI . Objective : To determine whether intracoronary infusion BMCs improve recovery leave ventricular function acute myocardial infarction treat PCI Design : Multi-center , randomize , control clinical trial central core lab analysis MRI . Therapy : Intracoronary infusion BMCs infarct related artery 5-7 day 3-4 week successful primary PCI Primary Endpoint : Change global leave ventricular ejection fraction ( LVEF ) 4 month relative baseline measure quantitative MRI . Secondary Endpoints : - Change LVEF MRI 12 month - Change regional leave ventricular wall motion thickness 4 12 month . - Change infarct size 4 12 month assess `` delayed enhancement '' technique MRI - Analysis myocardial infarct size transmurality , time PCI coronary flow characteristic PCI predictor LV remodel change cell therapy - Change myocardial perfusion 4 12 month - Change serum level amino-terminal pro-brain natriuretic peptide ( NT pro-BNP ) - Major adverse cardiac event ( MACE : death , myocardial infarction , TVR ( ACBP PCI , stroke , hospitalization cardiac reason ) 12 month Interventions : - Aspiration 50 ml bone marrow ( &lt; 24 hour ) prior administration - Intracoronary balloon-based infusion 10 ml BMCs - Cardiac MRI baseline ( resp . hospital discharge ) , 4 12 month Therapy group : Bone marrow-derived stem cell infusion successfully revascularized infarct related vessel day 5-7 day 21-28 . Control group : Management accord `` state art '' medical therapy successful primary PCI . Safety : A study independent `` safety committee '' analyze clinical result first 60 patient .</brief_summary>
	<brief_title>SWiss Multicenter Intracoronary Stem Cells Study Acute Myocardial Infarction ( SWISS-AMI )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Visual LVEF angiogram echocardiography ≤45 % Treatment primary PCI within 24 hour onset chest pain initial treatment thrombolysis within 12 hour follow PCI within 24 hour onset chest pain Significant regional LV wall motion dysfunction infarct related territory Age &gt; 18 year Abnormal regional wall motion outside infarct region Known previous myocardial infarction target vessel Known preexisting leave ventricular dysfunction ( EF &lt; 45 % prior admission ) Need revascularization non infarctrelated coronary within 4 month Preexisting symptom heart failure know cardiomyopathy Known active infection chronic infection HIV , HBV HCV Chronic inflammatory disease Serious concomitant disease life expectancy le one year Follow impossible ( fixed abode , etc ) Contraindication cardiac MRI ( i.e . pace maker , neurostimulator , claustrophobia ) Severe renal failure ( creatinine &gt; 250 mmol/l ) Relevant liver disease ( GOT &gt; 2x norm spontaneous INR &gt; 1,5 ) Anemia ( Hb &lt; 8.5 mg/dl ) , Thrombocytopenia ( &lt; 100.000/µl ) Pregnancy Participation clinical trial last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>acute myocardial infarction</keyword>
	<keyword>MRI</keyword>
	<keyword>bone marrow cell</keyword>
	<keyword>stem cell</keyword>
	<keyword>remodel</keyword>
</DOC>